Northern Trust Corp Humanigen, Inc Transaction History

Northern Trust Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.12 - $0.23 $6,840 - $13,110	57,003 Added 68.24%	140,542 $19,000
Q3 2022 Nov 14, 2022	SELL	$0.15 - $3.02 $29 - $588	-195 Reduced 0.23%	83,539 $15,000
Q2 2022 Aug 12, 2022	SELL	$1.76 - $3.33 $634,497 - $1.2 Million	-360,510 Reduced 81.15%	83,734 $148,000
Q1 2022 May 13, 2022	SELL	$1.81 - $3.97 $24,161 - $52,995	-13,349 Reduced 2.92%	444,244 $1.34 Million
Q4 2021 Feb 08, 2022	BUY	$3.66 - $8.22 $72,017 - $161,744	19,677 Added 4.49%	457,593 $1.7 Million
Q3 2021 Nov 15, 2021	BUY	$5.93 - $17.83 $1.55 Million - $4.67 Million	261,999 Added 148.93%	437,916 $2.6 Million
Q2 2021 Aug 13, 2021	BUY	$13.54 - $22.74 $1.32 Million - $2.22 Million	97,841 Added 125.32%	175,917 $3.06 Million
Q1 2021 May 12, 2021	BUY	$12.91 - $23.83 $52,414 - $96,749	4,060 Added 5.49%	78,076 $1.49 Million
Q4 2020 Feb 11, 2021	BUY	$7.97 - $21.66 $589,907 - $1.6 Million	74,016 New	74,016 $1.3 Million

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.